synthetic biology

Biotech By Adam Feuerstein

A new RNA-based drug startup launches with Rutgers science and money connections

Biotech By Adam Feuerstein

Belgian pharma UCB to buy Zogenix, maker of rare epilepsy treatment, for $1.9 billion

First Opinion By Jennifer Rubin Grandis

It’s all in the details: start-up packages and ongoing gender bias in academic medicine

First Opinion By Holly Fernandez Lynch and Keith Hamilton

Pharmacies shouldn’t be the only place to get Paxlovid, the new Covid pill

Health Tech By Mario Aguilar

What types of mental health apps actually work? A sweeping new analysis takes stock of the evidence

Health By Helen Branswell

After Omicron, we could use a break. We may just get it

Biotech By Matthew Herper

With $3 billion, Hal Barron and other biotech veterans launch a disease ‘reversal’ company

Pharmalot By Ed Silverman

Patent thickets are thwarting U.S. availability of lower-cost biosimilar medicines, study finds